# Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso

> **NCT06652737** · PHASE1 · COMPLETED · sponsor: **Sanaria Inc.** · enrollment: 75 (actual)

## Conditions studied

- Malaria Falciparum
- Malaria Infection

## Interventions

- **BIOLOGICAL:** PfSPZ-LARC2 Vaccine
- **BIOLOGICAL:** Normal Saline (Placebo)

## Key facts

- **NCT ID:** NCT06652737
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-04
- **Primary completion:** 2026-02-18
- **Final completion:** 2026-02-18
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652737, "Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06652737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*